Semaglutide भारतात: संपूर्ण रुग्ण मार्गदर्शक
BasicsIndia Access

Semaglutide भारतात: संपूर्ण रुग्ण मार्गदर्शक

Semaglutide भारतात रक्त साखर आणि वज़न दोनों साठी सबसे चर्चित GLP-1 RA में—diabetologist से या generic market से। Drug class (brand नाही) समझना informed decisions मध्ये मदद। Forms, dosing, cost, safety, CDSCO/RSSDI/ICMR—2026 generic, oral vs injectable, Schedule H budgeting।

Short answer

Semaglutide साप्ताहिक/दैनिक GLP-1 RA है, ICMR/RSSDI के अनुसार T2D आणि BMI ≥27.5 या ≥25 सह-रोग obesity साठी। प्रिस्क्रिप्शन, titration, CDSCO sourcing। मासिक ₹8,000–₹20,000, generic सस्ता। Oral/injectable अलग timing/storage। Kesho शिक्षण—प्रिस्क्राइब/बेचते नाही.

Key takeaways

  • Semaglutide GLP-1 RA—औषध वर्ग का अणु—lifestyle product नाही; CDSCO approval आणि Schedule H prescription अनिवार्य।
  • भारतात weekly injection आणि daily oral दोनों उपलब्ध; प्रत्येक की timing, storage, titration अलग।
  • RSSDI metformin/lifestyle अपर्याप्त हो तो semaglutide सहित GLP-1 RA—CVD/obesity comorbidity पर विशेष।
  • CDSCO-approved generic semaglutide 20–40% लागत कम, फक्त licensed pharmacy valid prescription safe।
  • Titration मध्ये मळमळ expected; escalation धीमी, Indian meal patterns adjust—weeks मध्ये tolerance।
  • Long-term: pharmacotherapy + medical nutrition therapy, quarterly follow-up, CDSCO-approved licensed pharmacy only।

Semaglutide काय है?

Semaglutide GLP-1 RA—gut hormone GLP-1 mimic: insulin release, glucagon कम, stomach emptying धीमा, appetite कम। Drug class, single brand नाही. CDSCO T2D आणि selected obesity BMI/comorbidity ICMR/RSSDI। SUSTAIN, STEP meaningful HbA1c/weight lifestyle के साथ। Schedule H prescription-only। Kesho prescribe/sell नाही—education। Prescription specific CDSCO product, principles class mechanism। Generic market molecule packaging से अधिक important।

Semaglutide

Long-acting GLP-1 RA weekly injection या daily oral—T2D/obesity medical supervision।

भारतात semaglutide कौन-से forms?

Subcutaneous weekly pens low dose gradual weeks—dose titration nausea कम। Oral daily empty stomach, 30 min before food। CDSCO, prescription। Generic lower price post-patent। Packaging manufacturer, batch, expiry verify। Pens 2–8°C; after <30°C weeks। Oral strict morning—empty-stomach skip absorption कम।

भारतात semaglutide किसे लाभ?

T2D: RSSDI metformin/lifestyle insufficient, CVD, obesity, hypoglycaemia। Weight: BMI ≥27.5 या ≥25 comorbidity ICMR। Thin-fat modest BMI risk—waist, visceral fat। Thyroid, pancreatitis, kidney, pregnancy, interactions assess। T1D/DKA नाही. CVD outcome benefit individualised।

Semaglutide dosing/titration कसे?

Doctor gradual escalation। Weekly 0.25 mg 4 weeks → 0.5, 1 mg+। Oral 3→7→14 mg। Skip/self-adjust = nausea, vomiting, stop risk। GI 4–8 weeks peak then adapt। Same weekly day, rotate sites। Missed >5 days skip—double नाही. Festival: reminders, travel storage।

Semaglutide formulations एक नज़र

  • विशेषता: Frequency — Weekly injection: साप्ताहिक — Oral: दैनिक
  • विशेषता: Administration — Weekly: Subcutaneous pen — Oral: खाली पोट, 30 min पहले
  • विशेषता: Titration — Weekly: 0.25 → 0.5 → 1 mg+ — Oral: 3 → 7 → 14 mg
  • विशेषता: Storage — Weekly: Refrigerate — Oral: Room temp label
  • विशेषता: Trade-off — Weekly: Needle; trial data — Oral: Strict timing; 30 min no food

2026 भारत semaglutide cost?

City/pharmacy/dose/innovator-generic vary। Injectable ₹8,000–₹20,000/month। CDSCO generic licensed only। Social-media/compounded advisories। Insurance obesity rare। Cost early discuss—stop without lifestyle regain। Tier-2 metro compare GST। Titration lower dose one pen at a time।

Registered practitioner valid prescription बिना semaglutide never purchase। Unapproved counterfeit/degraded/wrong dose risk।

Dr. Ananya Mehta

Medically reviewed

Dr. Ananya Mehta, MD, DM Endocrinology

Consultant Endocrinologist, India

This article has been reviewed by our medical advisory team, including endocrinologists, internal medicine specialists, and cardiologists, and is based on current scientific evidence and Indian clinical guidelines. Last reviewed: June 2026.

Last medically reviewed: Jun 26, 2026

Editorial policy · Medical advisory team